Clinical trials: 5-FU
Advanced Solid Tumor
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
QLC5508 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT07256782
- Testing
- QLC5508, QL1706, Cisplatin/ Carboplatin
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Gastric Cancer
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in…
- Trial name
- DG-03 (NCT04379596)
- Testing
- Fluorouracil (5-FU), Capecitabine, Durvalumab
- Where
- 71 sites in United States, Brazil and 12 more
- Volunteers
- 452 people
- Sponsor
- AstraZeneca
Neuroendocrine Carcinoma
A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
This Phase III, multicenter, randomized, open-label, controlled study is designed to assess the efficacy and safety of ZG006 versus investigator-selected chemotherapy in participants with DLL3-positive advanced neuroendocrine…
- Trial name
- NCT07595913
- Testing
- ZG006, 5-fluorouracil, Calcium folinate and Irinotecan
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Actinic Keratoses
Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment
This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria.
- Trial name
- NCT06274320
- Testing
- Group A: holistic approach, Group B: Tolak® Standard of use
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Head and Neck Cancer
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer.
- Trial name
- NCT00122460
- Testing
- Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU), Platinum (Cisplatin or Carboplatin) + 5-FU
- Where
- 70 sites in Austria, Belgium and 15 more
- Volunteers
- 442 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Trial name
- NCT00004252
- Testing
- fluorouracil, leucovorin calcium, semaxanib
- Where
- 26 sites in United States
- Sponsor
- Pfizer
Rectal Cancer
A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer
This phase Ib/II study is a prospective, open-label, single arm, nonrandomized study of PEP503(radio-enhancer). There are 2 portions in this study.
- Trial name
- NCT02465593
- Testing
- PEP503, 5-fluorouracil, capecitabine
- Where
- Taiwan
- Volunteers
- 32 people
- Sponsor
- PharmaEngine
Advanced Metastatic (Stage IV) Colorectal Cancer
A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer
The present trial is designed to determine whether pre-treatment with PledOx lowers the frequency and severity of side effects from FOLFOX6 administration in patients with metastatic colorectal cancer.
- Trial name
- PLIANT (NCT01619423)
- Testing
- PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg)
- Where
- 33 sites in United States, Bulgaria and 6 more
- Volunteers
- 186 people
- Sponsor
- Egetis Therapeutics AB (publ)
BRAF V600E, Metastatic Colorectal Cancer
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic…
- Trial name
- NAUTICALCRC (NCT05004350)
- Testing
- Encorafenib, Cetuximab, FOLFIRI
- Where
- 34 sites in China
- Volunteers
- 107 people
- Sponsor
- Pierre Fabre Medicament
Advanced Cancer
A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer
This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and capecitabine.
- Trial name
- NCT00710736
- Testing
- ARRY-334543, EGFR/ErbB2 inhibitor; oral, Capecitabine, 5-fluorouracil prodrug; oral
- Where
- 4 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Chemotherapy-induced Peripheral Neuropathy
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab
- Trial name
- NCT05251727
- Testing
- thrombomodulin alfa
- Where
- 32 sites in United States, Japan
- Volunteers
- 77 people
- Sponsor
- Veloxis Pharmaceuticals
Diarrhea
Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea
The main objective of this study will be to obtain data on the efficacy of elsiglutide in preventing Chemotherapy Induced Diarrhea (CID) in patients with colorectal cancer receiving 5-FU based chemotherapy (FOLFOX4 or FOLFIRI…
- Trial name
- NCT01543451
- Testing
- Elsiglutide
- Where
- 21 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 138 people
- Sponsor
- Helsinn Healthcare SA
Chronic Hepatitis C
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
The purpose of this study is to explore the efficacy and safety of TMC647055, TMC435, and low-dose ritonavir, administered together with and without ribavirin and of TMC647055, TMC435, low-dose ritonavir administered together…
- Trial name
- NCT01724086
- Testing
- TMC647055, TMC435, Ritonavir
- Where
- 10 sites in Belgium, Germany
- Volunteers
- 90 people
- Sponsor
- Janssen R&D Ireland
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic…
- Trial name
- NCT04662710
- Testing
- Pembrolizumab, Lenvatinib, Oxaliplatin
- Where
- 177 sites in United States, Argentina and 22 more
- Volunteers
- 895 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to…
- Trial name
- NCT02448810
- Testing
- BAX69 + infusional 5-FU/LV, BAX69 + panitumumab, BAX69 + 5-FU/LV
- Where
- 12 sites in United States
- Volunteers
- 115 people
- Sponsor
- Baxalta now part of Shire
Colorectal Neoplasms, Colonic Neoplasms
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- NCT00056459
- Testing
- Vatalanib
- Where
- 223 sites in United States, Australia and 17 more
- Volunteers
- 1,168 people
- Sponsor
- Novartis
Metastatic Colorectal Cancer
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as CMAB009, can block tumor growth in different ways.
- Trial name
- NCT03206151
- Testing
- CMAB009, Irinotecan, Folinic acid
- Where
- 2 sites in China
- Volunteers
- 520 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously…
- Trial name
- DIGEST (NCT01285557)
- Testing
- S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm), Fluorouracil/cisplatin (control arm)
- Where
- 87 sites in United States, Argentina and 18 more
- Volunteers
- 361 people
- Sponsor
- Taiho Oncology, Inc.
Colorectal Neoplasms, Neoplasm Metastasis
Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan…
- Trial name
- VELOUR (NCT00561470)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- Where
- 221 sites in United States, Argentina and 26 more
- Volunteers
- 1,226 people
- Sponsor
- Sanofi
Colo-rectal Cancer
A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
This is a multicenter, randomized, parallel-group, Phase III study in at least 440 patients with advanced colorectal cancer to compare the efficacy of treatment with arfolitixorin versus Leucovorin in combination with…
- Trial name
- AGENT (NCT03750786)
- Testing
- Arfolitixorin, Leucovorin
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 490 people
- Sponsor
- Isofol Medical AB